SCB Selects Robert Shaw as New Executive Director
The Standards Coordinating Body is pleased to welcome Robert (Bob) Shaw as its new Executive Director. Bob brings nearly 30 years of experience in the regenerative medicine and biotechnology fields, with expertise spanning technical, operational, strategic, and commercial development. His deep sector knowledge, industry acumen, and technical expertise will help guide SCB in its next phase of growth, as it works to shape standards that will drive scale and patient access for advanced therapies.
Bob formerly served as Vice President of Thermo Fisher Scientific, where he had global responsibility for the Bioproduction Division’s Technical Support Services and previously for their Cell Culture and Cell Therapy businesses. He implemented a number of innovations to drive growth and expansion, including strategic processes to improve the structure and function of their Field Scientist and Program Management functions. In previous roles at Progenitor Cell Therapy and EMD Millipore Corporation, he established new practices and partnerships to help growing teams excel and thrive. Bob has also been active as a board member and co-chair of the Alliance for Regenerative Medicine (ARM), including heading up ARM’s initial working group on standardization.
“The SCB team is very pleased to welcome Bob to our organization,” said SCB President Richard McFarland. “The regenerative medicine sector continues to grow, even amid COVID-19, and further standards development is essential. Bob’s expertise and proven leadership experience will help us continue to enable sustainable growth for advanced therapies.”
As Executive Director of SCB, Bob will lead the team’s day-to-day activities and translate SCB’s strategic direction into action. The Executive Director coordinates the activities of SCB staff, Board Members and committees, and volunteers, fostering clear communication and a positive organizational culture. As SCB continues to grow, Bob’s deep organizational development expertise and passion for regenerative medicine standards will be crucial to helping us sustain our momentum and continue to find ways to better serve the regenerative medicine community.
About SCB
The Standards Coordinating Body (SCB) is an independent non-profit organization focused on accelerated advancement and improved awareness of the standards and best practices that address the rapidly evolving needs of the global regenerative medicine advanced therapy community. SCB was founded in 2017 to support the growth of the regenerative medicine industry by the Alliance for Regenerative Medicine (ARM) and other regenerative medicine stakeholders. SCB works with a range of sector leaders, including the National Institute of Standards and Technology (NIST), to address areas critical to the growth of advanced therapies, such as standards for rapid microbial testing, cell collection, in-process labeling for cell collection, ancillary material quality, and more. Organizations that participate in SCB standards advancement activities help accelerate regenerative medicine innovation. SCB is based in the Washington DC area and encourages global, sector-wide participation in its standards advancement activities.